GAMMA Investing LLC Has $642,000 Stake in DexCom, Inc. (NASDAQ:DXCM)

GAMMA Investing LLC raised its holdings in DexCom, Inc. (NASDAQ:DXCM) by 47.6% during the 4th quarter, Holdings Channel reports. The institutional investor owned 8,258 shares of the medical device company’s stock after acquiring an additional 2,665 shares during the quarter. GAMMA Investing LLC’s holdings in DexCom were worth $642,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in DXCM. Versant Capital Management Inc acquired a new stake in shares of DexCom in the fourth quarter valued at about $25,000. Sachetta LLC grew its stake in DexCom by 255.2% in the second quarter. Sachetta LLC now owns 238 shares of the medical device company’s stock valued at $27,000 after purchasing an additional 171 shares in the last quarter. Riverview Trust Co increased its position in shares of DexCom by 100.4% during the 3rd quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock worth $31,000 after purchasing an additional 232 shares during the last quarter. RPg Family Wealth Advisory LLC bought a new stake in shares of DexCom during the 3rd quarter worth approximately $57,000. Finally, Covestor Ltd boosted its holdings in shares of DexCom by 53.7% in the 3rd quarter. Covestor Ltd now owns 959 shares of the medical device company’s stock valued at $64,000 after buying an additional 335 shares during the last quarter. 97.75% of the stock is owned by institutional investors.

DexCom Stock Up 3.3 %

DXCM stock opened at $81.07 on Friday. DexCom, Inc. has a 52 week low of $62.34 and a 52 week high of $142.00. The business has a 50-day simple moving average of $76.12 and a 200 day simple moving average of $80.54. The company has a quick ratio of 2.12, a current ratio of 2.46 and a debt-to-equity ratio of 1.23. The company has a market cap of $31.67 billion, a PE ratio of 48.55, a price-to-earnings-growth ratio of 2.46 and a beta of 1.12.

Insider Buying and Selling at DexCom

In related news, EVP Sadie Stern sold 4,259 shares of the stock in a transaction that occurred on Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total transaction of $318,275.07. Following the sale, the executive vice president now owns 71,192 shares in the company, valued at approximately $5,320,178.16. This trade represents a 5.64 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 0.30% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on DXCM shares. Oppenheimer dropped their price target on shares of DexCom from $115.00 to $105.00 and set an “outperform” rating on the stock in a research report on Friday, October 25th. Wells Fargo & Company upped their target price on shares of DexCom from $90.00 to $94.00 and gave the company an “overweight” rating in a report on Wednesday, December 11th. Citigroup raised their target price on shares of DexCom from $85.00 to $91.00 and gave the company a “buy” rating in a research note on Wednesday, December 11th. Sanford C. Bernstein boosted their price target on DexCom from $82.00 to $86.00 and gave the stock an “outperform” rating in a research report on Friday, October 25th. Finally, Raymond James cut their price objective on DexCom from $115.00 to $99.00 and set a “strong-buy” rating for the company in a research report on Friday, October 25th. Seven equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $98.00.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.